Hoth Therapeutics发布的最新雌性临床前研究数据显示，其候选药物HT-VA在代谢相关脂肪肝病（MASLD）动物模型中表现出显著疗效。实验结果表明，HT-VA能够有效恢复机体的胆固醇平衡，并优化脂质代谢通路。这一突破为开发针对代谢性肝病的新型疗法提供了有力支持。
Hoth Therapeutics发布的最新雌性临床前研究数据显示，其候选药物HT-VA在代谢相关脂肪肝病（MASLD）动物模型中表现出显著疗效。实验结果表明，HT-VA能够有效恢复机体的胆固醇平衡，并优化脂质代谢通路。这一突破为开发针对代谢性肝病的新型疗法提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.